Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
A phase 2 trial of durvalumab and cisplatin in gallbladder cancer and other biliary tract cancers, run by Insel Gruppe AG, University Hospital Bern, now recruiting.
Overview
Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer is a phase 2, randomised interventional study registered as NCT06274879 by Insel Gruppe AG, University Hospital Bern, with a registry enrolment figure of 36 participants, started 2026-05-20 and due to reach its primary completion in 2029-12-30. Interventions recorded: Gemcitabin, Cisplatin and Durvalumab, Biliary Radiofrequency Ablation, Endoscopic Retrograde Cholangio-Pancreatography with stenting. Conditions listed: Bile Duct Cancer. Sites: Switzerland. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialMP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents and the tag gallbladder-deep-dive.
- TrialCTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialDurvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialPerioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialQL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialAdebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialAlternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialDurvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.